Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Csl Ltd ADR
(OP:
CSLLY
)
101.84
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Csl Ltd ADR
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
April 26, 2024
FDA approves Pfizer's Beqvez for adults with hemophilia B, offering a one-time treatment to produce FIX. Experience reduced bleeding frequency. Explore Pfizer's warranty program.
Via
Benzinga
Exposures
Product Safety
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
December 13, 2023
Canaccord Genuity has initiated coverage on Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT), a player in the genetic medicine space.
Via
Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
5 Diverse Medical Stocks To Buy For 2023 And Beyond
April 08, 2023
Healthcare will always be essential to society, making many health companies viable investments for growth. A look at the five top-rated stocks that investors may want to consider buying for 2023 and...
Via
Talk Markets
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
March 20, 2023
Reuters
Via
Benzinga
Arcturus Shares Jump After Collaboration With CSL For mRNA-Based Vaccines
November 02, 2022
Via
Benzinga
CSL Posts Encouraging Data From Garadacimab In Severe Swelling Attacks
August 17, 2022
Via
Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
March 20, 2023
Via
Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
November 23, 2022
Via
Benzinga
Why Is Arcturus Therapeutics (ARCT) Stock Up 30% Today?
November 02, 2022
The run-up in ARCT stock is practically unstoppable as two science-focused firms collaborate to develop mRNA technology.
Via
InvestorPlace
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
August 22, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product
May 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
CSL Seals $11.7B Buyout Deal Of Vifor Pharma, Probably the Largest Healthcare Deal In 2021
December 14, 2021
Australian biopharma CSL Ltd (OTC: CSLLY) has agreed to acquire Vifor Pharma AG (OTC: GNHAY) for $11.7 billion (equity value) in a move to diversify...
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.